Who are Butylphthalide Soft Capsules's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NeuroAiD, Xaliproden (SR57746A), Edaravone Dexborneol Sequential Therapy, Hi-dose iv MgSO4, Butylphthalide soft capsule, DMB-I (INN: Latrepirdine).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/butylphthalide-soft-capsules.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Butylphthalide Soft Capsules — Competitive Intelligence Brief

Butylphthalide Soft Capsules (Butylphthalide Soft Capsules) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuroprotective agent. Area: Neurology.

marketed Neuroprotective agent Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Butylphthalide Soft Capsules (Butylphthalide Soft Capsules) — Peking Union Medical College Hospital. Butylphthalide protects brain cells by improving mitochondrial function and reducing oxidative stress and inflammation following ischemic stroke.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Butylphthalide Soft Capsules TARGET	Butylphthalide Soft Capsules	Peking Union Medical College Hospital	marketed	Neuroprotective agent
NeuroAiD	NeuroAiD	CHIMES Society	marketed	Herbal neuroprotective agent
Xaliproden (SR57746A)	Xaliproden (SR57746A)	Sanofi	phase 3	Neuroprotective agent	NMDA receptor
Edaravone Dexborneol Sequential Therapy	Edaravone Dexborneol Sequential Therapy	Simcere Pharmaceutical Co., Ltd	phase 3	Neuroprotective agent combination
Hi-dose iv MgSO4	Hi-dose iv MgSO4	Hamad Medical Corporation	phase 3	NMDA receptor antagonist / Neuroprotective agent	NMDA receptor
Butylphthalide soft capsule	Butylphthalide soft capsule	Capital Medical University	phase 3	Neuroprotective agent	Mitochondrial function modulator (non-specific)
DMB-I (INN: Latrepirdine)	DMB-I (INN: Latrepirdine)	Bigespas LTD	phase 3	Neuroprotective agent	NMDA receptor, mitochondrial membrane, monoamine oxidase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuroprotective agent class)

Bigespas LTD · 1 drug in this class
Capital Medical University · 1 drug in this class
Peking Union Medical College Hospital · 1 drug in this class
Rong Hu, MD · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Butylphthalide Soft Capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/butylphthalide-soft-capsules. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab